Open Access
CC BY-NC-ND 4.0 · Endosc Int Open 2020; 08(08): E1068-E1069
DOI: 10.1055/a-1196-1458
Editorial

Should we incorporate topical epinephrine in the ESGE guideline on prevention of post-ERCP pancreatitis?

E. Toussaint
Department of Gastroenterology, Charleroi University Hospitals, Charleroi, Belgium
,
J.-M. Dumonceau
Department of Gastroenterology, Charleroi University Hospitals, Charleroi, Belgium
› Institutsangaben
Preview

Pancreatitis remains the most frequent and lethal adverse event (AE) that may follow endoscopic retrograde cholangiopancreatography (ERCP). Fortunately, it is also the only AE for which significant advances have been made. Since 2010, four scientific societies have issued guidelines about the prophylaxis of post-ERCP pancreatitis (PEP). All of them have recommended rectal nonsteroidal anti-inflammatory drugs (NSAIDs) as the cornerstone of pharmacological prophylaxis of PEP ([Table 1]).



Publikationsverlauf

Artikel online veröffentlicht:
21. Juli 2020

© 2020. Owner and Copyright ©

© Georg Thieme Verlag KG
Stuttgart · New York